Summary The guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) do not recommend the measurement of pulmonary artery pressure in patients with chronic obstructive pulmonary disease (COPD). This is on the basis that the mean pulmonary artery pressure (mPAP) does not provide more clinical information than measurement of the oxygen tension in arterial blood (PaO 2 ). The mPAP correlates well with PaO 2 in emphysema patients with severe hypoxemia (PaO 2 p7.3 kPa (55 mmHg)). However, the occurrence and significance of mPAP is unclear in patients without severe hypoxemia (PaO 2 47.3 kPa (55 mmHg)). In order to evaluate the usefulness of measurement of mPAP in emphysema patients without severe hypoxemia, we performed right heart catheterization and investigated the pulmonary hemodynamics of 53 patients without severe hypoxemia. In addition, we identified long-term prognostic factors with a mean follow-up term of 77 months after right heart catheterization. Seventeen of 27 patients with mild-to-moderate hypoxemia exhibited pulmonary hypertension (mPAPX2.7 kPa (20 mmHg)) and the classification according to severity in GOLD exhibited a greater correlation to mPAP than PaO 2 . Moreover, only mPAP was found to be a significant prognostic factor according to multivariate proportional hazards analysis (P ¼ 0:01). We conclude that mPAP is more informative about the severity of emphysema than PaO 2 in patients with mild-tomoderate hypoxemia. r
Introduction
The prognostic factors in chronic obstructive pulmonary disease (COPD) patients with severe hypoxemia (PaO 2 p7.3 kPa (55 mmHg)) have been well analyzed. Forced expiratory volume in 1 s (FEV 1.0 ), arterial blood gas values (PaO 2 and PaCO 2 ; carbon dioxide tension in arterial blood), age, nutritional status, dyspnea and mean pulmonary artery pressure (mPAP) have been demonstrated to be good indicators of patient prognosis. [1] [2] [3] [4] [5] Several studies have indicated that long-term oxygen therapy (LTOT) stabilizes and may even reverse the progression of pulmonary hypertension, [6] [7] [8] [9] and has been shown to result in improved survival in hypoxemic COPD patients. According to these observations, the current indications for this therapy are the severity of the hypoxemia (PaO 2 p7.3 kPa) or pulmonary hypertension and right heart failure at a PaO 2 of 7.3-8.0 kPa.
On the other hand, the occurrence of pulmonary hypertension remains unclear in patients without In the present study, we investigated pulmonary hemodynamic parameters using cardiac catheterization in emphysema patients without severe hypoxemia (PaO 2 47.3 kPa) and evaluated the significance of mPAP measurement.
Materials and methods
Fifty-three patients with a diagnosis of pulmonary emphysema without severe hypoxemia (PaO 2 4 7.3 kPa) were obtained from those patients treated at Kure National Hospital from 1985 to 1993. This study was performed as the work of a research and investigation team for respiratory failure in the Ministry of Health and Welfare of Japan, and was approved by the clinical research committee of the Institute. Written informed consent was obtained from all patients. Patients underwent right heart catheterization and were followed up to August 1999. In this study, emphysema was defined on both clinical and functional criteria. We selected patients with emphysema prior to the initiation of LTOT who were dyspneic on exertion and whose FEV 1.0 /vital capacity ratio (FEV 1.0 %) was less than 70% when they were free of acute exacerbation. We examined the complete clinical history, physical examination findings and the results of basic laboratory tests of the patients. mPAP and mixed venous oxygen tension were measured by SwanGanz balloon-tipped catheters in the supine position without premedication. Cardiac output was calculated according to Fick's principle. Pulmonary and static volumes were measured twice by conventional spirometry with an interval of 4 weeks and arterial blood gas levels were measured while breathing room air after a 15 min resting period in the supine position. Patients with sleep apnea syndrome, left heart disease and/or other severe diseases such as malignant tumors, hepatic cirrhosis and chronic renal failure that could influence their survival were excluded from the study. Bronchodilators such as theophylline, b 2 agonists and anticholinergic drugs were prescribed to most patients during the study period. Antibiotics, diuretics, and corticosteroids were prescribed at the discretion of physicians.
We divided the patients according to the degree of obstruction into four groups according to GOLD: Stage I: percent of FEV 1 
Statistical analysis
Data are expressed as mean and standard deviation. Differences of measured variables between groups were assessed using analysis of variance and Kruskal-Wallis test. P values less than 0.05 were considered to be statistically significant. Survival was calculated from the day when the cardiac catheterization was performed to the day the patient died or to the end of the study. The multivariate analysis of factors affecting survival was performed by Cox's model of proportional hazards regression. Survival curves were drawn using the Kaplan-Meier method and the log-rank statistic was used to confirm the lack of difference in survival between two groups.
Results

Patients
The study group included 49 men and four women (mean age 7177.6 years) ( Table 1 ). The average of follow-up period was 76.7 months (range: 2-161 months). The degree of dyspnea was 2.771.0 according to the American Thoracic Society (ATS) scale. The serum albumin and blood hemoglobin were 609772 mmol/l (4.270.5 g/dl) and 9.07 0.9 mmol/l (14.571.5 g/dl), respectively, while the body mass index was 18.972.9 kg/m 2 . The FEV 1.0 %pred, percent of vital capacity (%VC), PaO 2 and PaCO 2 were 39.8716.2%, 73.0719.3%, 9.571.2 kPa (70.979.0 mmHg) and 5.670.8 kPa (41.975.7 mmHg), respectively. The mPAP was 2.570.6 kPa (19.074.3 mmHg) ( Table 2) .
Relationship between the degree of hypoxemia and pulmonary artery pressure
We divided the patients according to the PaO 2 values into three groups (Table 1) : moderate hypoxemia, 7.3oPaO 2 p8.7 kPa (55oPaO 2 p (65oPaO 2 p70 mmHg); and normal, PaO 2 49.3 kPa (70 mmHg). The mPAP of these patient groups were 2.870.5 kPa (21.274.1 mmHg), 2.770.6 kPa (20.574.4 mmHg) and 2.370.5 kPa (17.17 3.5 mmHg), respectively. The patients with mildto-moderate hypoxemia (7.3oPaO 2 p9.3 kPa) exhibited a significantly higher pulmonary artery pressure than those with a normal PaO 2 (PaO 2 4 9.3 kPa, P ¼ 0:0009). Seventeen of 27 (63%) patients with mild-to-moderate hypoxemia exhibited pulmonary hypertension (mPAP42.7 kPa (20 mmHg)).
Relationship between the classification by severity in gold and hypoxemia and mPAP Fig. 1 depicts the prevalence of PaO 2 and mPAP according to the staging system for COPD described in GOLD. The prevalence of PaO 2 showed no significant difference between stages according to FEV 1.0 %pred (Fig. 1A) . However, mPAP increased significantly according to increased severity of airflow limitation (Fig. 1B) . There was a good correlation between mPAP and FEV 1.0 %pred (R ¼ 0:494; P ¼ 0:0002) while PaO 2 also exhibited a significant correlation with FEV 1.0 %pred (R ¼ 0:303; P ¼ 0:03).
Analysis of prognostic factors
Seventeen of the 53 patients were alive at the end of the study while 36 patients had died, with the deaths of 21 being directly related to worsening of (Fig. 1B) . mPAP was well correlated with the stages defined by GOLD (Po0:0001) (Fig. 1B) . their emphysema. The other 15 patients died of various conditions including malignant tumors, pneumonia and ileus. The prognostic factors in 38 patients, i.e. excluding the patients who died of diseases other than respiratory failure, are shown in Table 3 . The log-rank test indicated that mPAP, dyspnea (ATS scale), age and PVR were significant prognostic factors. However, only mPAP was demonstrated to be significant (P ¼ 0:01) following subsequent multivariate proportional hazards analysis.
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We then divided the 53 patients according to the mPAP values into two groups. The survival curves of the groups with and without pulmonary hypertension (mPAPX2.7 kPa and mPAPo2.7 kPa) are shown in Fig. 2 . The group with pulmonary hypertension included 23 patients and the group without pulmonary hypertension consisted of 30 patients. Statistical analysis indicated that the patients with pulmonary hypertension had a significantly worse prognosis (P ¼ 0:0001).
Discussion
In our study, all patients did not exhibit severe hypoxemia. However, according to the staging system in GOLD, 64% of our patients were classified as Stage IIB and 26% were classified as Stage III. PaO 2 values did not exhibit a significant difference between the stages according to GOLD, whereas mPAP demonstrated a significant increase according to increased severity of airflow limitation and correlated with the stages defined by GOLD. This result indicates that mPAP is a more useful indicator of the severity of emphysema than PaO 2 in patients without hypoxemia. MPAP in Stage III was 2.870.7 kPa (20.774.9 mmHg) and pulmonary Figure 2 Cumulative survival rate for patients with pulmonary hypertension (mPAPX2.7 kPa) and those without pulmonary hypertension (mPAPo2.7 kPa). The group with pulmonary hypertension consisted of 23 patients and the group without pulmonary hypertension consisted of 30 patients. The patients with pulmonary hypertension exhibited a significantly worse prognosis (P ¼ 0:0001). vascular resistance as a whole average was 21.7 kPa/l (normal range: 4.5-10 kPa/l), on the other hand, cardiac index was within normal range and erythrocytosis was not recognized. All of our patients did not exhibit any symptoms of right heart failure at the cardiac catheterization, therefore the prevalence of pulmonary hypertension could not have been predicted. Scharf et al. 10 evaluated 120 emphysema patients without severe hypoxemia, and showed that DL CO %, PCWP and FEV 1.0 %pred but not PaO 2 were significant predictors of mPAP by multiple regression analysis. In comparison with our patients, the patients studied by Scharf et al. had considerably more severe disease, e.g. the mean values of their FEV 1.0 %pred and mPAP were 27% and 3.5 kPa (26.3 mmHg), respectively. This result is in accordance with our data in that the pulmonary artery pressure increased according to increased severity of airflow limitation, and supports our consideration that mPAP is more sensitive and may reflect the severity of disease better than PaO 2 in emphysema patients without severe hypoxemia. The prognostic value of the presence of pulmonary hypertension in COPD patients with severe hypoxemia is in accordance with the results obtained by previous investigators. [1] [2] [3] [4] [5] On the other hand, in patients with mild-to-moderate hypoxemia the prognostic value of pulmonary hypertension has been unclear. In our study, mPAP, dyspnea (ATS scale), age and PVR were found to be significant prognostic factors in univariate analysis. However, in subsequent multivariate analysis, only mPAP was found to be significant. The studies of Gorecka et al. 11 and Anthonisen et al. 12 indicated that younger age, better spirometric values and higher body mass index were predictors of improved survival in COPD patients with mild-tomoderate hypoxemia. In our study, univariate analysis of long-term prognostic factors indicated that, similar to their results, age was a prognostic factor but spirometric values were not prognostic factors. Anthonisen et al. 12 indicated that patients with low initial values of FEV 1.0 showed relatively little decline of FEV 1.0 % during the observation period. Our subjects showed lower initial values of FEV 1.0 %pred than the patients in their study, and this may explain why FEV 1.0 %pred was not a significant prognostic factor in our study.
ARTICLE IN PRESS
On the other hand, univariate analysis indicated that patients with severe dyspnea (ATS scale IV) exhibited a worse prognosis than patients with mild-to-moderate dyspnea (ATS scale I, II, III). A strong correlation was recognized between dyspnea and mPA (jRj ¼ 0:67) and FEV 1.0 %pred (jRj ¼ 0:61), although the correlation coefficient with PaO 2 was 0.15. This result suggests that patients exhibiting severe dyspnea even with light exercise have severe airway limitation and pulmonary hypertension even in the absence of severe hypoxemia at rest.
Multivariate analysis showed that only mPAP was an independent prognostic factor. However, the progression of mPAP in COPD patients has been observed to be very slow, as the average increase of mPAP was 0.4-0.5 mmHg/yr. 13, 14 Kessler et al.
14 assessed the evolution of pulmonary hemodynamics in 131 COPD patients with mild-to-moderate hypoxemia without pulmonary hypertension by performing two right heart catheterizations at a mean time interval of 6.8 year. In their study, the resting and exercising mPAP at the onset were independent predictors for the subsequent development of pulmonary hypertension. Moreover, in patients with an accelerated worsening of resting mPAP a significant worsening of exercising mPAP was recognized between two intervals, whereas the changes of FEV 1.0 and PaO 2 were not significant. Our study does not have complete data regarding pulmonary hemodynamics during exercise; however, the findings of Kessler et al. 14 suggest the possibility that our patients with high mPAP showed marked elevation of mPAP on exercise and/or significant worsening of exercising mPAP in progress.
Right heart catheterization is the most accurate method for the evaluation of pulmonary hemodynamics but it is not performed routinely because it is invasive and expensive. Instead, various noninvasive approaches have been used including imaging techniques such as nuclear medicine, real-time sonography, color Doppler echography, CT and MRI. 15, 16 Recently, Matsuyama et al. 17 demonstrated that the transcutaneous measurement of jugular venous flow velocity by Doppler jugular venous echo might have a potential role in the prediction of pulmonary hypertension. In emphysema patients, lung hyperinflation has made the assessment of right ventricular volumes problematic and this transcutaneous Doppler jugular venous echo may therefore be a useful tool to monitor pulmonary artery pressure. In summary, the prevalence of pulmonary hypertension was high in emphysema patients with mildto-moderate hypoxemia, and only mPAP was a significant prognostic factor by multivariate analysis. Although our study has some limitations because of the small number of subjects, mPAP exhibited a greater correlation than PaO 2 with the staging system of severity in GOLD in patients without severe hypoxemia. However, the values of mPAP were various in patients of each stage as shown in Fig. 1 ., therefore we need to evaluate the patients with high mPAP appropriately and followup and prevent its progression.
